Partnership Opportunities

Investment into CKD has never been greater, and as large pharma and emerging biotech companies continue to expand their renal pipelines, the need for greater patient diversity across clinical trials, sophisticated biomarker screens to stratify best responders to SGLT2s, and robust models recapitulating the complex pathophysiology of specific forms of CKD become greater and greater. The 6th CKD Drug Development Summit presented a timely and unrivalled opportunity for your company to stay ahead of the curve and position yourself at the forefront of the minds of highly engaged experts prioritizing rare and chronic kidney diseases.

Download the event guide to learn more about how you could have showcased your brand and capitalized on our audience of leading companies with active pipelines in CKD, IgAN, Lupus Nephritis, FSGS, CG3 and other cardiorenal indications. 

Why Partner Next Year:

Icon booth

Secure an exhibition booth to present and position your capabilities to developers who are actively seeking new solutions to optimize drug development inefficiencies.

Icon network

Network one-to-one with stakeholders during our coordinated networking sessions to first-hand understand their requirements and present your solution.

Icon presentation

Deliver a presentation and influence the thinking of preclinical, translational, and clinical decision makers working to identify new promising compounds and drive success in the clinic.

Our 2024 Partners

NATERA
george clinical
nordic
seastarr-image
antaros medical
medibeacon
newcells
ENYO Pharma_Logo_No background (002)
chinook_logo (002)
vera
IgAN-fullcolor-logo
Logo Physiogenex
almac
2023_gubra_logo-blue
Alpine Logo Stacked
Perspectum_RGB_NoTM (1)

Regeneron, Eli Lilly, Novo Nordisk, Novartis, GSK and AstraZeneca were amongst our other 200+ attendees that were seeking partners to help them in the following areas:

Icon rd

Contract Research – accelerate and support preclinical and clinical R&D and position yourself as the leading CRO in rare and common kidney disorders

Icon kidney

Non-Invasive Biomarkers – communicate your capabilities to enhance the development and validation of fluid and imaging biomarkers to detect CKD at an earlier stage and more precisely monitor renal function

Icon preclinical

Preclinical Models – showcase your expertise in developing translatable, validated in vivo or in vitro models that reliably predict how drugs interact within human kidney tissue